Rahul Aggarwal

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
    Rahul R Aggarwal
    Department of Medicine, University of California San Francisco, San Francisco, CA Electronic address
    Clin Genitourin Cancer 13:e191-8. 2015
  2. doi Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment
    Rahul Aggarwal
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA Electronic address
    Clin Genitourin Cancer 12:e167-72. 2014
  3. doi Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Rahul R Aggarwal
    Division of Hematology Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Urol Oncol 31:522-30. 2013
  4. pmc Castration-resistant prostate cancer: targeted therapies and individualized treatment
    Rahul Aggarwal
    Department of Medicine, University of California, San Francisco, CA 94143 1270, USA
    Oncologist 16:264-75. 2011
  5. pmc The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
    Rahul Aggarwal
    Division of Hematology Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Cancer 119:3636-43. 2013
  6. doi The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels
    Rahul Aggarwal
    Urologic Oncology Program, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 7:E71-6. 2009
  7. doi Somatostatin imaging of neuroendocrine-differentiated prostate cancer
    Thomas A Hope
    From the Department of Radiology and Biomedical Imaging, Division of Hematology Oncology, Department of Medicine, Departments of Pathology, Urology, and Radiation Oncology, University of California San Francisco, San Francisco, CA
    Clin Nucl Med 40:540-1. 2015
  8. ncbi Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes
    Rahul Aggarwal
    From the aDepartment of Medicine, Division of Hematology Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, and Department of Medicine, and bDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina
    J Natl Compr Canc Netw 12:719-26. 2014

Detail Information

Publications8

  1. doi Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
    Rahul R Aggarwal
    Department of Medicine, University of California San Francisco, San Francisco, CA Electronic address
    Clin Genitourin Cancer 13:e191-8. 2015
    ....
  2. doi Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment
    Rahul Aggarwal
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA Electronic address
    Clin Genitourin Cancer 12:e167-72. 2014
    ..Docetaxel or AA are therapeutic options for mCRPC. We retrospectively analyzed clinical outcomes with subsequent docetaxel in patients with mCRPC after disease progression (DP) with AA to evaluate cross resistance between these therapies...
  3. doi Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Rahul R Aggarwal
    Division of Hematology Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Urol Oncol 31:522-30. 2013
    ..Using the development of IR and/or obesity may represent a clinically available biomarker that may predict those patients most likely to respond to such therapy, and warrants testing in future prospective clinical trials...
  4. pmc Castration-resistant prostate cancer: targeted therapies and individualized treatment
    Rahul Aggarwal
    Department of Medicine, University of California, San Francisco, CA 94143 1270, USA
    Oncologist 16:264-75. 2011
    ..Additionally, lessons learned through the application of these technologies to prostate cancer may subsequently influence therapeutic development in other solid tumors...
  5. pmc The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
    Rahul Aggarwal
    Division of Hematology Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Cancer 119:3636-43. 2013
    ....
  6. doi The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels
    Rahul Aggarwal
    Urologic Oncology Program, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 7:E71-6. 2009
    ..This current analysis reports the relationship of change in adrenal androgen levels and prostate-specific antigen (PSA) response in patients with CRPC treated with estrogen therapy...
  7. doi Somatostatin imaging of neuroendocrine-differentiated prostate cancer
    Thomas A Hope
    From the Department of Radiology and Biomedical Imaging, Division of Hematology Oncology, Department of Medicine, Departments of Pathology, Urology, and Radiation Oncology, University of California San Francisco, San Francisco, CA
    Clin Nucl Med 40:540-1. 2015
    ..We describe a case of NEPC successfully imaged using In-labeled octreotide. ..
  8. ncbi Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes
    Rahul Aggarwal
    From the aDepartment of Medicine, Division of Hematology Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, and Department of Medicine, and bDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina
    J Natl Compr Canc Netw 12:719-26. 2014
    ....